ResearcherTokyo Dental College Ichikawa General HospitalActive in the last 2 years
Junichi Matsui
Matched on ORCID iD 0000-0003-1393-0488; OpenAlex author ID A5042672134. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 6
- Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Cancer (TOSPAC-02): A Phase 2 Clinical Tria… Co-author DOI 10.1245/s10434-025-17661-7↗
- Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Co-author DOI 10.1002/cam4.7459↗
- Investigating the early diagnosis of pancreatic cancer by surveillance of patients with "K-sign" of the pancreas by computed tomography: A prospective study. First author DOI 10.1002/jhbp.1411↗
- The "K-Sign"-A Novel CT Finding Suggestive before the Appearance of Pancreatic Cancer. Last author DOI 10.3390/cancers13164222↗
- Introducing the "K-Shaped Sign", A New Finding on CT to Detect Early-Stage Pancreatic Cancer First author DOI 10.20944/preprints201912.0250.v1↗
- Corrigendum to "Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative rese… Co-author DOI 10.1016/j.pan.2016.12.014↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yutaka Takigawa · 3 shared papers, 2024–2025 · strength 0.68
- Paper Investigating the early diagnosis of pancreatic cancer by surveillance of patients with "K-sign" of the pancreas by com… DOI 10.1002/jhbp.1411↗
- Paper Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Can… DOI 10.1245/s10434-025-17661-7↗
- Paper Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. DOI 10.1002/cam4.7459↗
- Koichi Aiura · 3 shared papers, 2017–2025 · strength 0.49
- Paper Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Can… DOI 10.1245/s10434-025-17661-7↗
- Paper Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. DOI 10.1002/cam4.7459↗
- Paper Corrigendum to "Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitom… DOI 10.1016/j.pan.2016.12.014↗
- Yuko Kobashi · 2 shared papers, 2019–2021 · strength 0.42
- Yutaka Endo · 2 shared papers, 2024–2025 · strength 0.40
- Minoru Kitago · 2 shared papers, 2024–2025 · strength 0.40
- Yuta Abe · 2 shared papers, 2024–2025 · strength 0.40
- Yutaka Nakano · 2 shared papers, 2024–2025 · strength 0.40
- Yuko Kitagawa · 2 shared papers, 2017–2025 · strength 0.31
- Paper Perioperative 5-Fluorouracil and Portal Vein Infusion Chemotherapy Followed by Adjuvant S-1 for Resected Pancreatic Can… DOI 10.1245/s10434-025-17661-7↗
- Paper Corrigendum to "Beneficial effects of 5-fluorouracil and heparin-based portal infusion chemotherapy combined with mitom… DOI 10.1016/j.pan.2016.12.014↗
- Aya Sasaki · 1 shared paper, 2024 · strength 0.28
- Sojun Hoshimoto · 1 shared paper, 2025 · strength 0.22
- Yosuke Uematsu · 1 shared paper, 2025 · strength 0.22
- Yuko Kitagawa · 1 shared paper, 2024 · strength 0.18
- Minoru Tanabe · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.